TY - JOUR
T1 - A global subsidy
T2 - Key to affordable drugs for malaria?
AU - Laxminarayan, Ramanan
AU - Gelband, Hellen
PY - 2009/7
Y1 - 2009/7
N2 - The global fight against malaria has been continually challenged by poor access to affordable, effective medicine. Growing resistance to chloroquine, the traditional treatment, has worsened the situation. Artemisinins, the successor therapy to chloroquine, are at least ten times more costly than the older drug. In developing countries, most malaria medicines are purchased in the private sector, where traditional aid mechanisms do not reach. So a new aid approach was needed. The Affordable Medicines Facility-malaria (AMFm) will efficiently supply publicly subsidized drugs to meet public- and private-sector demand in malaria-endemic countries. If artemisinins are priced more competitively, resistance to them will be delayed.
AB - The global fight against malaria has been continually challenged by poor access to affordable, effective medicine. Growing resistance to chloroquine, the traditional treatment, has worsened the situation. Artemisinins, the successor therapy to chloroquine, are at least ten times more costly than the older drug. In developing countries, most malaria medicines are purchased in the private sector, where traditional aid mechanisms do not reach. So a new aid approach was needed. The Affordable Medicines Facility-malaria (AMFm) will efficiently supply publicly subsidized drugs to meet public- and private-sector demand in malaria-endemic countries. If artemisinins are priced more competitively, resistance to them will be delayed.
UR - http://www.scopus.com/inward/record.url?scp=67651207370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651207370&partnerID=8YFLogxK
U2 - 10.1377/hlthaff.28.4.949
DO - 10.1377/hlthaff.28.4.949
M3 - Review article
C2 - 19597193
AN - SCOPUS:67651207370
SN - 0278-2715
VL - 28
SP - 949
EP - 961
JO - Health Affairs
JF - Health Affairs
IS - 4
ER -